COVID Vaccine Immunity in Kidney Transplant Recipients

University of Alabama at Birmingham

Overview

50 end-stage renal disease (ESRD) patients whom have had at least 2 doses of messenger ribonucleic acid (mRNA) vaccine, and undergoing transplantation at the University of Alabama at Birmingham (UAB) will be enrolled. The third mRNA vaccine will be given 3 months post transplant, and the 4th mRNA vaccine will be given 3 months following this. Blood samples will be collected and shipped to Viracor on day of transplant, and at months 1, 3, 4, 6, and 12 for spike protein and t cell assay.

50 ESRD patients on peritoneal dialysis or hemodialysis or not on immunosuppression, no prior transplant, no known history of COVID infection, whom have had at least 2 doses of mRNA vaccine, and undergoing transplantation at UAB will be enrolled, after signing the informed consent. The third mRNA vaccine will be given 3 months post transplant, and the 4th mRNA vaccine will be given 3 months following this. Blood samples will be collected and shipped to Viracor on day of transplant, and at months 1, 3, 4, 6, and 12 for spike protein and t cell assay.

Study Type

OBSERVATIONAL

Conditions

End Stage Renal Disease Kidney Transplant; Complications

Interventions

Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity TestDIAGNOSTIC_TEST

Boosters will be given after month 3 after transplant, and the 2nd booster will be given 3 months after the first.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * End Stage Renal Disease patients on peritoneal dialysis or hemodialysis or not on immunosuppression * no prior transplant * no known history of COVID infection * had at least 2 doses of mRNA COVID vaccine * undergoing transplantation at the University of Alabama at Birmingham * multi-organ transplant allowed Exclusion Criteria: * active COVID infection * participant is not vaccinated against COVID